Benefits for Healthcare

Improving outcomes, identifying non-responders and reducing the cost of care are all crucial to healthcare providers. Want to deliver precision medicines for everyone? We can help you do just that.

The benefits of precision medicine are giving the right drug to the right patient at the right time. This requires a detailed understanding of complex diseases, better diagnostic biomarkers and tools to enable the selection of the drug or drugs most likely to help a specific patient.

Our unique, high-resolution insights map all of the disease relevant targets at which existing drugs act to predict which ones could be used to help patients with currently unmet medical needs. Our disease signatures are useful patient stratification biomarkers that, coupled with our deep annotation of targets-existing drugs, enable prediction of the likely responses of members of a patient sub-group to various medicines.

Our 5Rs Framework for precision medicine delivery ensures we deliver the right:

We analyse disease susceptibility, progression and treatment strategies for patient sub-groups in complex diseases with a goal to understand and be able to predict the likely responses and outcomes for an individual patient.

We can analyze longitudinal patient records to identify responses to therapies and evaluate the impact of those medications (whether approved for that disease or not) on the disease phenotype. We can integrate this knowledge with deep genomic, epigenetic, epidemiological and other patient data to identify markers describing patient sub-groups most likely to benefit from specific medications.

We enable patient stratification for clinical trial design and interpretation, as well as personalized disease risk scores for diagnosis, prognosis & therapy response.

Being able to identify which sub-group of a disease a patient belongs to is critical to finding the most effective therapy for them. We can identify patient sub-groups based on combinations of features (genomic, phenotypic and clinical), and suggest the drugs to which that sub-group is likely to respond (or not).

Clinicians have to rapidly weigh up evidence from multiple sources – clinical, genetic, diagnostic etc – and synthesize it to come to an evidence-led decision about which therapies to prescribe.

We can help healthcare providers to build clinical decision support and therapy selection tools for their clinicians and patients. Our precisionlife platform includes a rigorous rule-based decision support framework that can apply all of the detailed genomic, phenotypic, clinical and outcomes data into a knowledge model that can drive personalized decision support tools.

As well as giving the right drug at the right time to the right patient, we need to ensure that we have evidence that the right outcomes can be achieved for those patients. For multi-morbid and polypharmaceutical patients this includes the selection of personalized treatments that provide the desired outcome for that patient while minimizing the chance of creating adverse drug reactions (side effects).

This involves considering the drug:drug, drug:disease and even drug:food interactions that are reported in the literature. As there are hundreds of thousands of these, bringing that knowledge into routine clinical practice requires simple, quick and fully personalized tools. We have built demonstrators of this new generation of fully personalized recommendation tools1.

1 Gardner, S., Pawlowski, M., Møller, G.L., & Jensen, C.E., Delivering personalized dietary advice for health management and disease prevention Digital Medicine (2018) 4:127-132 18 Oct, 2018 (DOI: 10.4103/digm.digm_19_18)

There have been fantastic advances in the development of novel therapeutics, especially in complex diseases. Many of these patient benefits have come from treatments involving biologic drugs, immunomodulation and cell therapy. While hugely valuable in the clinical arsenal, these therapies are very expensive to deliver. Spending on biologics vs. small molecule therapies has increased significantly and accounts for almost all of the increase in drug spending since 20141. In 2017, while biologic drugs represented just 2% of all US prescriptions, they accounted for 37% of net drug spending.

Unfortunately while these are ground-breaking and pivotal for the treatment of some patients, they do not work for others. It is therefore even more important to have a principled, evidence-led basis on which to prescribe these new therapies.

1 IQVIA Institute Report. Medicine Use and Spending in the US. April 2018 

Interested in licensing or partnering?